While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn't match the effects seen with the injectable ...

External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes. Expert Opinion on Pharmacotherapy. Accepted June 6 ...

GLP-1 drugs show promise in diabetes management, offering heart and kidney benefits, but also highlight the need for ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

A recent study found that older adults with diabetes who use a GLP-1 drug have double the risk of developing wet age-related ...

Bottom line of study: SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...